

Endometrial Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/E089094DD04DEN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: E089094DD04DEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Endometrial Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Endometrial Cancer Understanding

Endometrial Cancer: Overview

Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly. The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body.

'Endometrial Cancer - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometrial Cancer pipeline landscape is provided which includes the disease overview and Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Endometrial Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Endometrial Cancer.

Endometrial Cancer Emerging Drugs Chapters

This segment of the Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometrial Cancer Emerging Drugs

Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. The drug is in pre-registration stage of development for the treatment of Endometrial cancer.

Lenvatinib (LENVIMA): Eisai Co Ltd

LENVIMA is an orally administered kinase inhibitor with a novel binding mode that selectively inhibits the multi activities of vascular endothelial growth factor (VEGF)

receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFR?; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity. The drug is registered for the treatment of endometrial cancer.

Further product details are provided in the report.....

Endometrial Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Endometrial Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endometrial Cancer

There are approx. 5+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. preregistration include GlaxoSmithKline.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endometrial Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endometrial Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometrial

Cancer drugs.

Endometrial Cancer Report Insights

Endometrial Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Endometrial Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Endometrial Cancer drugs?

How many Endometrial Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometrial Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Endometrial Cancer

therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Endometrial Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

GlaxoSmithKline

Eisai Co Ltd

MedImmune

On Target Laboratories

Sutro Biopharma

Netris Pharma

Key Products

Dostarlimab

Lenvatinib

Durvalumab

Pafolacianine

STRO-002

NP137

Contents

Introduction

Executive Summary

Endometrial Cancer: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Endometrial Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Endometrial Cancer companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Endometrial Cancer Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration)

- Comparative Analysis

Dostarlimab: GlaxoSmithKline

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Pafolacianine: On Target Laboratories

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

STRO 002: Sutro Biopharma

- Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Endometrial Cancer- Market Drivers and Barriers

Endometrial Cancer- Future Perspectives and Conclusion

Endometrial Cancer Analyst Views

Endometrial Cancer Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Endometrial Cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Endometrial Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Endometrial Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/E089094DD04DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E089094DD04DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970